Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Illumina ($ILMN) announced the launch of a new DNA sequencer with new architecture. The new sent the stock over 11% up in the pre-market session. The company said that the new architecture may lower the costs of decoding human genome considerably. Illumina is of the view that the costs may become as low as $100.
The new DNA sequencers NovaSeq 5000 and NovaSeq 6000 have lower per sample consumable costs. The company said that the new sequencer systems will help in creating in new markets as these can make routine a wide range of applications, such as ultra-deep sequencing of matched tumor-normal pairs and large-scale variant discovery studies associated with complex diseases.

Galena Biopharma ($GALE) reported that it is being investigated by the U.S. Attorney's Office for the District of New Jersey and the U.S. Department of Justice. The company is undergoing both criminal and civil investigation.
The investigations are related to the marketing and promotional practices associated with opioid Abstral (fentanyl) sublingual tablets. The investigations will seek whether the company is guilty of possible violations of the federal False Claims Act, the federal Anti-Kickback Statute and the federal Sunshine Act.
Galena also reported receiving a subpoena for documents related to the criminal prosecution of two high-prescribing physicians. The company intends to cooperated with the inquiry.


• DaVita Healthcare Partners ($DVA) reported it's received a subpoena from a U.S. district attorney seeking information tied to charitable premium assistance.
• Sangamo BioSciences ($SGMO) announced changing its name to Sangamo Therapeutics. The company’s stock symbol will remain the same.

• Roche ($RHHBY) announced that the FDA has approved its Lucentis (ranibizumab) for treating patients with myopic choroidal neovascularization, a complication of severe near-sightedness that can lead to blindness.
• PTC Therapeutics' ($PTCT) announced that its Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy, has been conditionally approved by the European Commission for another year.

• Arrowhead Pharmaceuticals ($ARWR) stock jumped on the news of Silence Therapeutics acquiring some of its common stock.
• Valeant ($VRX) announced selling its Dandreon business to China’s Sanpower Group. The deal is said to be worth $819.9 million.

• Incyte Corp. ($INCY) received Buy rating from BMO Capital. The price target for the stock is set at $135.
• Iridex Corp.($IRIX) received Buy rating from Roth Capital. The price target for the stock is set at $20.

Gainers (% price change) Last Trade Change Mkt Cap
Ariad Pharmaceuticals
23.75 +10.01 (72.85%) 4.73B
90.79 +20.02 (28.29%) 7.37B
CTI BioPharma Corp
5.78 +0.98 (20.42%) 175.60M
EXACT Sciences Corp.
17.98 +2.88 (19.07%) 1.94B
NewLink Genetics Corp
13.12 +2.03 (18.30%) 389.62M
Losers (% price change)
AMAG Pharmaceuticals, Inc
23.00 -12.70 (-35.57%) 783.53M
AtriCure Inc.
16.59 -2.34 (-12.36%) 551.74M
BioCryst Pharmaceuticals
6.34 -0.79 (-11.08%) 481.12M
Emergent Biosolutions Inc
32.04 -2.62 (-7.56%) 1.35B
Immunomedics, Inc.
3.48 -0.25 (-6.70%) 367.70M
Most Actives (dollar volume)
Ariad Pharmaceuticals
23.75 +10.01 (72.85%) 4.73B
90.79 +20.02 (28.29%) 7.37B
Celgene Corporation
120.21 +0.57 (0.48%) 93.88B
Gilead Sciences, Inc.
75.84 +0.35 (0.46%) 99.23B
Medtronic PLC
73.82 +0.95 (1.30%) 101.36B